drugset / Trial / NCT00382837

Study of Epratuzumab in Systemic Lupus Erythematosus

NCT00382837

Phase 3 Withdrawn UCB Pharma
Non-randomizedSingle-groupOpen-labelTreatment

Summary

Epratuzumab is an investigational antibody designed to help treat SLE. The purpose is to evaluate safety and long term efficacy in concert with standard SLE treatments

Timeline

Start
2007-01
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Epratuzumab Monoclonal antibody